Midodrine for Ischemic Stroke With Penumbra "MISP"


Phase N/A Results N/A

Summary of Purpose

Acute ischemic stroke (AIS) affects over 700,000 Americans every year and is the leading cause of long-term disability. Early neurological deterioration after AIS typically occurs within 72 hours of stroke onset and affects 30% of all stroke patients, who have a higher rate of death or poor outcome. Several mechanisms... Trial Stopped: Changed study to an observational study

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 15 May 2017.

10 May 2017 27 Feb 2015 10 May 2017 10 May 2017 1 May 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

  • Allocation: Randomized
  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Single Group Assignment
  • Sampling: Non-Probability Sample


Not available